CompletedPhase 1NCT01967758

Phase I Study of Safety and Immunogenicity of ADU-623

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Providence Health & Services
Principal Investigator
Marka Crittenden, MD, PhD
Providence Health & Services
Intervention
Cohort 1(biological)
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
20142018

Study locations (1)

Collaborators

Aduro Biotech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01967758 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials